ArticleTranslational lung cancer research2025
Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small cell lung cancer (SCLC) is characterized by an aggressive clinical course and poor survival rates. The introduction of immune checkpoint blockade (ICB) into the frontline treatment of extensive-stage (ES)-SCLC with programmed death-ligand 1 (PD-L1) inhibitors such as atezolizumab and durvalumab has improved outcomes. However, median overall survival (OS) is still limited to approximately 12 months, underscoring the need for predictive biomarkers to optimize treatment selection. Notably, recent subgroup analyses suggest potential sex-specific differences in response to ICB, with improved outcomes observed in female patients. However, the biological mechanisms underlying these differences remain unclear. Additionally, metabolic factors may influence response to immunotherapy, yet their roles in ES-SCLC remain underexplored. This study aims to evaluate the impact of sex and metabolic phenotypes on treatment outcomes in ES-SCLC patients receiving atezolizumab and to identify potential metabolic biomarkers of response. Methods: This retrospective single-center study evaluated the impact of sex and metabolic phenotypes on treatment outcomes in ES-SCLC patients receiving atezolizumab. Seventy patients were analyzed: 33 treated with atezolizumab plus chemotherapy (September 2019 to May 2024) and 37 historical controls who received chemotherapy alone (January 2014 to September 2019). Primary endpoints were OS and progression-free survival (PFS). Additionally, targeted metabolomic profiling was performed using nuclear magnetic resonance (NMR) spectroscopy on serum samples from 12 patients receiving atezolizumab, yielding 55 serum samples for analysis. Results: Our study replicated the OS benefit of atezolizumab, with the greatest advantage observed in female patients (median OS: 20.2 Conclusions: These findings support the hypothesis that both sex and metabolic factors modulate responses to ICB in ES-SCLC. Further research is warranted to validate these biomarkers and explore potential interventions to enhance immunotherapy efficacy in this aggressive malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.